This invention relates to the fields of pharmacology and chemical biology, particularly application of α-Mangostin in preparation of medicaments for Alzheimer's disease.
BACKGROUND OF THE INVENTION
Alzheimer's disease is a progressive fatal neurodegenerative disease manifesting cognitive and memory deterioration, proceeding diminishing of daily activities, with a variety of neurological symptoms and behavioral disorders.
Aβ aggregation and deposition is an important pathological process in the development of Alzheimer's disease. During the process of Aβ aggregation and deposition, Aβ oligomer with strong nerve toxicity, and senile plaque, one of the pathological hallmarks of Alzheimer's disease, can be formed. Studies have shown that injecting the aggregation of Aβ can induce the occurrence of Alzheimer's disease-like symptoms in mice, while the pathological symptoms of Alzheimer's disease could be relieved by inhibiting Aβ aggregation and deposition, such as the capability of learning and memorializing could be improved in both preclinical (cell models or animal models) and clinical researches. Therefore, the inhibitors of Aβ aggregation and deposition have been promised the potential application in the treatment of Alzheimer's disease, and the development of such inhibitors has become an important direction in the studies of Alzheimer's disease.
α-Mangostin is an extract from garcinia mangostana (also known as Garcinia mangostana L., garcinia mangostana, or mangosteen) used as a traditional medicine in Southeast Asia, which mainly consists in a nutshell of mangosteen and now can be synthesized artificially. Structure formula of α-Mangostin is as follows: